China · Delayed Price · Currency is CNY Luyan Pharma Statistics
Total Valuation
Luyan Pharma has a market cap or net worth of CNY 6.49 billion. The enterprise value is 11.06 billion.
| Market Cap | 6.49B |
| Enterprise Value | 11.06B |
Important Dates
The next estimated earnings date is Tuesday, April 21, 2026.
| Earnings Date | Apr 21, 2026 |
| Ex-Dividend Date | Jul 10, 2025 |
Share Statistics
Luyan Pharma has 388.52 million shares outstanding. The number of shares has decreased by -0.25% in one year.
| Current Share Class | 388.52M |
| Shares Outstanding | 388.52M |
| Shares Change (YoY) | -0.25% |
| Shares Change (QoQ) | +1.88% |
| Owned by Insiders (%) | 3.50% |
| Owned by Institutions (%) | 0.37% |
| Float | 232.41M |
Valuation Ratios
The trailing PE ratio is 20.89.
| PE Ratio | 20.89 |
| Forward PE | n/a |
| PS Ratio | 0.31 |
| PB Ratio | 1.99 |
| P/TBV Ratio | 2.50 |
| P/FCF Ratio | 19.23 |
| P/OCF Ratio | 10.65 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.65, with an EV/FCF ratio of 32.76.
| EV / Earnings | 35.92 |
| EV / Sales | 0.53 |
| EV / EBITDA | 14.65 |
| EV / EBIT | 17.84 |
| EV / FCF | 32.76 |
Financial Position
The company has a current ratio of 1.10, with a Debt / Equity ratio of 1.53.
| Current Ratio | 1.10 |
| Quick Ratio | 0.77 |
| Debt / Equity | 1.53 |
| Debt / EBITDA | 6.63 |
| Debt / FCF | 14.82 |
| Interest Coverage | 3.28 |
Financial Efficiency
Return on equity (ROE) is 9.69% and return on invested capital (ROIC) is 6.06%.
| Return on Equity (ROE) | 9.69% |
| Return on Assets (ROA) | 3.05% |
| Return on Invested Capital (ROIC) | 6.06% |
| Return on Capital Employed (ROCE) | 16.40% |
| Weighted Average Cost of Capital (WACC) | 5.48% |
| Revenue Per Employee | 3.73M |
| Profits Per Employee | 54,974 |
| Employee Count | 5,602 |
| Asset Turnover | 1.64 |
| Inventory Turnover | 7.08 |
Taxes
In the past 12 months, Luyan Pharma has paid 99.46 million in taxes.
| Income Tax | 99.46M |
| Effective Tax Rate | 24.40% |
Stock Price Statistics
The stock price has increased by +105.52% in the last 52 weeks. The beta is 0.59, so Luyan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | +105.52% |
| 50-Day Moving Average | 15.85 |
| 200-Day Moving Average | 10.32 |
| Relative Strength Index (RSI) | 43.05 |
| Average Volume (20 Days) | 61,677,319 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Luyan Pharma had revenue of CNY 20.91 billion and earned 307.96 million in profits. Earnings per share was 0.80.
| Revenue | 20.91B |
| Gross Profit | 1.49B |
| Operating Income | 619.94M |
| Pretax Income | 407.72M |
| Net Income | 307.96M |
| EBITDA | 692.35M |
| EBIT | 619.94M |
| Earnings Per Share (EPS) | 0.80 |
Balance Sheet
The company has 459.18 million in cash and 5.00 billion in debt, with a net cash position of -4.55 billion or -11.70 per share.
| Cash & Cash Equivalents | 459.18M |
| Total Debt | 5.00B |
| Net Cash | -4.55B |
| Net Cash Per Share | -11.70 |
| Equity (Book Value) | 3.26B |
| Book Value Per Share | 8.34 |
| Working Capital | 917.19M |
Cash Flow
In the last 12 months, operating cash flow was 609.46 million and capital expenditures -271.85 million, giving a free cash flow of 337.61 million.
| Operating Cash Flow | 609.46M |
| Capital Expenditures | -271.85M |
| Free Cash Flow | 337.61M |
| FCF Per Share | 0.87 |
Margins
Gross margin is 7.14%, with operating and profit margins of 2.96% and 1.47%.
| Gross Margin | 7.14% |
| Operating Margin | 2.96% |
| Pretax Margin | 1.95% |
| Profit Margin | 1.47% |
| EBITDA Margin | 3.31% |
| EBIT Margin | 2.96% |
| FCF Margin | 1.61% |
Dividends & Yields
This stock pays an annual dividend of 0.35, which amounts to a dividend yield of 2.08%.
| Dividend Per Share | 0.35 |
| Dividend Yield | 2.08% |
| Dividend Growth (YoY) | 16.67% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 106.59% |
| Buyback Yield | 0.25% |
| Shareholder Yield | 2.24% |
| Earnings Yield | 4.74% |
| FCF Yield | 5.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 29, 2019. It was a forward split with a ratio of 1.7.
| Last Split Date | May 29, 2019 |
| Split Type | Forward |
| Split Ratio | 1.7 |
Scores
Luyan Pharma has an Altman Z-Score of 2.29 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.29 |
| Piotroski F-Score | 5 |